Forget Ozempic: This Obesity-Drug Giant Grabs GLP-1 Gold
As GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
As GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...